IPMN, Pancreatic
13
6
8
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 13 trials
8%
1 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (13)
The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
Venous Resection in Patients Undergoing Pancreatic Surgery
AI-Powered Precision Decision-Making for Pancreatic Diseases
Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)
Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst bIomarkers Detection (INCITE) Consortium
Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)
Identification of New Theranostic Biomarkers of Pancreatic Tumor Progression
Impact of GLP-1 Receptor Agonists on Patients With IPMN
Pancreatic Cancer Initial Detection Via Liquid Biopsy
Intraductal Papillary Mucinous Neoplasm (IPMN) Database - A Tool to Predict Pancreatic Cancer
A Long-term Follow-up Cohort Study in Patients With Intraductal Papillary Mucinous Neoplasm